Heartflow (NASDAQ:HTFL) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

Heartflow (NASDAQ:HTFL) had its price target raised by equities researchers at Canaccord Genuity Group from $35.00 to $39.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target suggests a potential upside of 8.73% from the stock’s current price.

Several other equities research analysts have also weighed in on HTFL. Wall Street Zen upgraded Heartflow to a “hold” rating in a research report on Saturday, August 16th. Stifel Nicolaus initiated coverage on Heartflow in a research report on Tuesday, September 2nd. They set a “buy” rating and a $35.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on shares of Heartflow in a research note on Tuesday, September 2nd. They issued an “overweight” rating and a $36.00 price target for the company. Morgan Stanley assumed coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They set an “equal weight” rating and a $35.00 price target for the company. Finally, Piper Sandler assumed coverage on shares of Heartflow in a report on Tuesday, September 2nd. They issued an “overweight” rating and a $38.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $36.60.

Heartflow Trading Up 14.1%

NASDAQ:HTFL opened at $35.87 on Monday. Heartflow has a 12 month low of $26.56 and a 12 month high of $36.68.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings data on Friday, September 19th. The company reported ($1.46) EPS for the quarter, missing the consensus estimate of ($0.20) by ($1.26). The business had revenue of $43.42 million for the quarter, compared to analyst estimates of $43.20 million.

About Heartflow

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.